{
  "ticker": "LLY",
  "target_date": "2025-09-25",
  "actual_date": "2025-09-25",
  "collected_at": "2025-12-08T12:19:35.770381",
  "price": {
    "open": 736.59,
    "high": 738.91,
    "low": 711.01,
    "close": 713.5421142578125,
    "volume": 5136400,
    "change_1d_pct": -3.67,
    "change_7d_pct": -6.55,
    "change_30d_pct": 8.43
  },
  "technicals": {
    "rsi_14": 44.53,
    "sma_20": 744.38,
    "sma_50": 734.13,
    "macd": 3.276,
    "macd_signal": 6.255,
    "macd_histogram": -2.979,
    "bb_upper": 770.4,
    "bb_lower": 718.37,
    "price_vs_sma20_pct": -4.14,
    "price_vs_sma50_pct": -2.8,
    "volume_ratio": 1.56
  },
  "fundamentals": {
    "market_cap": 892507848704,
    "pe_ratio": 48.779762,
    "forward_pe": 43.93623,
    "price_to_book": 37.484753,
    "price_to_sales": 15.020378,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.47,
    "pct_from_52w_low": 59.61
  },
  "macro": {
    "spy": {
      "price": 658.05,
      "change_1d_pct": -0.46,
      "change_7d_pct": 0.11
    },
    "vix": {
      "level": 16.74,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.17
    },
    "dollar_index": {
      "level": 98.55
    },
    "gold": {
      "price": 3736.9
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease",
      "source": "Yahoo",
      "datetime": 1758839940,
      "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the European Commission (EC) has granted marketing authorization for Kisunla (donanemab) for the treatment of early symptomatic Alzheimer's disease (AD), in adults with mild cognitive impairment as well as those with mild dementia stages of AD w",
      "url": "https://finnhub.io/api/news?id=01d7dd0c9e31b4f45980ec2bc74cee5a4efadf5143722d13f84f3b52588fb388"
    },
    {
      "headline": "Eli Lilly (LLY) Stock Trades Down, Here Is Why",
      "source": "Yahoo",
      "datetime": 1758833441,
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.1% in the afternoon session after the company halted a mid-stage clinical trial for its experimental drug, bimagrumab, which was intended to prevent muscle loss in patients taking its blockbuster obesity treatment, Zepbound.",
      "url": "https://finnhub.io/api/news?id=cca304d74cf4474372df6835ab1afe8c4728d12db1875b5a17d14a6365ea0425"
    },
    {
      "headline": "Eli Lilly Presses Pause On Zepbound-Bimagrumab Diabetes Study",
      "source": "Yahoo",
      "datetime": 1758829199,
      "summary": "Zepbound-bimagrumab study scrapped, other research still ongoing",
      "url": "https://finnhub.io/api/news?id=454dbcc8cf015ddb6e85f60e510cb3c264741a0ee638cb8a94e165df8ce1c284"
    },
    {
      "headline": "Eli Lilly Gets European Authorization for Alzheimer's Treatment",
      "source": "MarketWatch",
      "datetime": 1758826800,
      "summary": "Eli Lilly Gets European Authorization for Alzheimer's Treatment",
      "url": "https://finnhub.io/api/news?id=bb75b656ebab6d6d805899bf9ff7667bd072b0798bf458655fa87eaab77e43ac"
    },
    {
      "headline": "U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer",
      "source": "Yahoo",
      "datetime": 1758823260,
      "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Inluriyo (imlunestrant, 200 mg tablets), an oral estrogen receptor antagonist, for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-n",
      "url": "https://finnhub.io/api/news?id=66a53e8d0fd4af1e311c572a4754f1fe50097a27785a4fe6b494252c76f9ee99"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-09-22",
      "description": "xslF345X05/form4-09222025_040901.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000009/xslF345X05/form4-09222025_040901.xml"
    },
    {
      "form": "4",
      "date": "2025-09-19",
      "description": "xslF345X05/form4-09192025_040901.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000007/xslF345X05/form4-09192025_040901.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142191.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000126238825000004/xslF345X05/wk-form4_1758142191.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142140.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000242/xslF345X05/wk-form4_1758142140.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142082.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000134082325000006/xslF345X05/wk-form4_1758142082.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}